Medical Oncology

, Volume 27, Supplement 1, pp 1–6 | Cite as

The evolution and impact of therapy in multiple myeloma

  • Jacob P. LaubachEmail author
  • Paul G. Richardson
  • Kenneth C. Anderson
Original Paper


Multiple myeloma is a clonal B-cell malignancy characterized by aberrant expression of plasma cells wtihin the bone marrow, and is associated with the well known clinical manifestations anemia, bone disease, renal dysfunction, hypercalcemia, and recurrent infections. For many years, melphalan and prednisone represented the standard of care in multiple myeloma therapy, with stem cell transplantation reserved for selected patients. Treatment of the disease has evolved rapidly over the past decade, however, with the development and utilization of thalidomide, lenalidomide, and bortezomib. As a result of these developments, clinical outcomes have improved significantly. This review highlights important historic landmarks as well as more recent events that have played an important role in the evolution of myeloma therapy.


Multiple myeloma Stem cell transplantation Lenalidomide Thalidomide Bortezomib 


Conflict of interest statements

Jacob P. Laubach: Advisory Board Novartis Pharmaceuticals.

Paul G. Richardson: Advisory Board Celgene Corporation, Millennium Pharmaceuticals Speakers Bureau Celgene Corporation, Millennium Pharmaceuticals.

Kenneth C. Anderson: Advisory Board Celgene Corporation, Millennium Pharmaceuticals; Consultant Celgene Corporation and Millennium Pharmaceuticals; Research support Celgene Corporation & Millennium Pharmaceuticals.

The authors received an honorarium for their participation in this supplement.


  1. 1.
    McKenna RW, Kyle RA, Kuehl WM, Grogan TM, Harris NL, Couplan RW. Plasma cell neoplasms. In: Swedlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2008.Google Scholar
  2. 2.
    Solly S. Remarks on the pathology of mollities ossium with cases. Med Chir Trans Lond. 1844;27:435–61.Google Scholar
  3. 3.
    Kyle RA. Multiple myeloma: an odyssey of discovery. Br J Haematol. 2000;111(4):1035–44.CrossRefPubMedGoogle Scholar
  4. 4.
    Bence Jones H. Chemical pathology. Lancet. 1847;2:88–92.CrossRefGoogle Scholar
  5. 5.
    Bence Jones H. On the new substance occurring in the urine of a patient with mollities ossium. Philos Trans R Soc Lond. 1848;138:55–62.CrossRefGoogle Scholar
  6. 6.
    Edelman GM, Gally JA. The nature of Bence-Jones proteins. Chemical similarities to polypetide chains of myeloma globulins and normal gamma-globulins. J Exp Med. 1962;116:207–27.CrossRefPubMedGoogle Scholar
  7. 7.
    Waldenstrom J. Studies on conditions associated with disturbed gamma globulin formation (gammopathies). Harvey Lect. 1961;56:211–31.Google Scholar
  8. 8.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49.CrossRefPubMedGoogle Scholar
  9. 9.
    Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21–33.CrossRefPubMedGoogle Scholar
  10. 10.
    Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–20.CrossRefPubMedGoogle Scholar
  11. 11.
    Weder C. Case reports: urethane in the treatment of multiple myeloma. Can Med Assoc J. 1950;62:589–90.PubMedGoogle Scholar
  12. 12.
    Rundles RW, Dillon ML, Dillon ES. Multiple myeloma. III. Effect of urethane therapy on plasma cell growth, abnormal serum protein components, and bence jones proteinuria. J Clin Invest. 1950;29:1243–60.CrossRefPubMedGoogle Scholar
  13. 13.
    Holland JF, Hosley H, Scharlau C, Carbone PP, Frei E, Brindley CO, et al. A controlled trial of urethane treatment in multiple myeloma. Blood. 1966;27(3):328–42.PubMedGoogle Scholar
  14. 14.
    Blokhin N, Larionov L, Perevodchikova N, Chebotareva L, Merkulova N. Clinical experiences with sarcolysin in neoplastic diseases. Ann N Y Acad Sci. 1958;68(3):1128–32.CrossRefPubMedGoogle Scholar
  15. 15.
    Bergsagel DE, Sprague CC, Austin C, Griffith KM. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806). Cancer Chemother Rep. 1962;21:87–99.PubMedGoogle Scholar
  16. 16.
    Hoogstraten B, Sheehe PR, Cuttner J, Cooper T, Kyle RA, Oberfield RA, et al. Melphalan in multiple myeloma. Blood. 1967;30(1):74–83.PubMedGoogle Scholar
  17. 17.
    Korst DR, Clifford GO, Fowler WM, Louis J, Will J, Wilson HE. Multiple myeloma. II. Analysis of cyclophosphamide therapy in 165 patients. JAMA. 1964;189:758–62.PubMedGoogle Scholar
  18. 18.
    Tourtellotte CR, Call MK. Prolonged remission of myeloma with cyclophosphamide. Arch Intern Med. 1964;113:758–63.PubMedGoogle Scholar
  19. 19.
    Salmon SE, Shadduck RK, Shilling A. Intermittent high-dose prednisone (NSC-10023) therapy for multiple myeloma. Cancer Chemother Rep. 1967;51:179–87.PubMedGoogle Scholar
  20. 20.
    Maas RE. A comparison of the effect of prednisone and a placebo in the treatment of multiple myeloma. Cancer Chemother Rep. 1962;16:257–9.Google Scholar
  21. 21.
    Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood. 1992;80:887–90.PubMedGoogle Scholar
  22. 22.
    Frei E, Holland JF, Schneiderman MA, Pinkel D, Silkirk G, Freireich EJ, et al. A comparative study of two regimens of combination chemotherapy in acute leukemia. Blood. 1958;13:1126–48.PubMedGoogle Scholar
  23. 23.
    Sampey JR. Combination chemotherapy in Hodgkin’s disease. Am Pract Dig Treat. 1961;12:589–92.PubMedGoogle Scholar
  24. 24.
    Greenspan EM, Fieber M. Combination chemotherapy of advanced ovarian carcinoma with the antimetabolite, methotrexate, and the alkylating agent, thioTEPA. J Mt Sinai Hosp NY. 1962;29:48–62.Google Scholar
  25. 25.
    Alexanian R, Haut A, Khan AU, Lane M, McKelvey EM, Migliore PJ, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA. 1969;208(9):1680–5.CrossRefPubMedGoogle Scholar
  26. 26.
    Lee BJ, Sahakian G, Clarkson BD, Krakhoff IH. Proceedings: combination chemotherapy of multiple myeloma with alkeran, cytoxan, vincristine, prednisone, and BCNU. Cancer. 1974;1974(33):533–8.CrossRefGoogle Scholar
  27. 27.
    Cooper MR, McIntyre OR, Propert KJ, Kochwa S, Anderson K, Coleman M, et al. Single, sequential, and multiple alkylating agent therapy for multiple myeloma: a CALGB study. J Clin Oncol. 1986;4(9):1331–9.PubMedGoogle Scholar
  28. 28.
    Samson D, Gaminara E, Newland A, et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet. 1989;II:882–5.CrossRefGoogle Scholar
  29. 29.
    Group MTC. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6, 633 patients from 27 randomized trials. J Clin Oncol. 1998;16:3832–42.Google Scholar
  30. 30.
    Blade J, San Miguel J, Fontanillas M, Esteven J, Maldonado J, Alcala A, et al. Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients. Hematol J. 2001;2:272–8.CrossRefPubMedGoogle Scholar
  31. 31.
    McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukemia and myeloma. Lancet. 1983;II(8354):822–4.CrossRefGoogle Scholar
  32. 32.
    Barlogie B, Hall R, Zander A, Dicke K, Alexanian R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood. 1986;67(5):1298–301.PubMedGoogle Scholar
  33. 33.
    Selby PJ, McElwain TJ, Nandi AC, Perren TJ, Powles RL, Tillyer CR, et al. Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol. 1987;66(1):55–62.PubMedGoogle Scholar
  34. 34.
    Dimopoulos MA, Alexanian R, Przepiorka D, Hester J, Andersson B, Giralt S, et al. Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood. 1993;82(8):2324–8.PubMedGoogle Scholar
  35. 35.
    Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. Autologous bone marrow transplantation versus conventional chemotherapy in multiple myeloma: a prospective, randomized trial. New Eng J Med. 1996;335:91–7.CrossRefPubMedGoogle Scholar
  36. 36.
    Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875–83.CrossRefPubMedGoogle Scholar
  37. 37.
    Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495–502.CrossRefPubMedGoogle Scholar
  38. 38.
    Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol. 2007;25(17):2434–41.CrossRefPubMedGoogle Scholar
  39. 39.
    Berenson JR, Crowley JJ, Grogan TM, Zangmeister J, Briggs AD, Mills GM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood. 2002;99(9):3163–8.CrossRefPubMedGoogle Scholar
  40. 40.
    Salmon SE, Crowley JJ, Balcerzak SP, Roach RW, Taylor SA, Rivkin SE, et al. Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol. 1998;16(3):890–6.PubMedGoogle Scholar
  41. 41.
    Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006;108:3289–94.CrossRefPubMedGoogle Scholar
  42. 42.
    Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354:1021–30.CrossRefPubMedGoogle Scholar
  43. 43.
    Spencer A, Prince HM, Roberts AW, Prosser IW, Bradstock KF, Coyle L, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol. 2009;27(11):1788–93.CrossRefPubMedGoogle Scholar
  44. 44.
    Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol. 2007;138:176–85.CrossRefPubMedGoogle Scholar
  45. 45.
    Curti A, Tosi P, Comoli P, Terragna C, Ferri E, Cellini C, et al. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. Br J Haematol. 2007;139(3):415–24.PubMedCrossRefGoogle Scholar
  46. 46.
    Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen EJ. Graft-versus-myeloma effect in two cases. Lancet. 1996;347:800–1.CrossRefPubMedGoogle Scholar
  47. 47.
    Bjorkstrand BB, Ljungman P, Svensson H, Hermans J, Alegre A, Apperley J, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood. 1996;88:4711–8.PubMedGoogle Scholar
  48. 48.
    Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood. 2003;102:3447–54.CrossRefPubMedGoogle Scholar
  49. 49.
    Rosinol L, Perez-Simon JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood. 2008;112(9):3591–3.CrossRefPubMedGoogle Scholar
  50. 50.
    Bruno B, Rotta M, Patriarca F, Mattei D, Allione B, Carnevale-Schianca F, et al. Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood. 2009;113(14):3375–82.CrossRefPubMedGoogle Scholar
  51. 51.
    Rotta M, Storer BE, Sahebi F, Shizuru JA, Bruno B, Lange T, et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and non-myeloablative allografting. Blood. 2009;113(14):3383–91.CrossRefPubMedGoogle Scholar
  52. 52.
    D’Amato RJ, Loughman MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91:4082–5.CrossRefPubMedGoogle Scholar
  53. 53.
    Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol. 1994;87:503–8.CrossRefPubMedGoogle Scholar
  54. 54.
    Vacca A, Di Loreto M, Ribatti D, Di Stefano R, Gadaleta-Caldarola G, Iodice G, et al. Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44. Am J Hematol. 1995;50(1):9–14.CrossRefPubMedGoogle Scholar
  55. 55.
    Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341(21):1565–71.CrossRefPubMedGoogle Scholar
  56. 56.
    Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367:825–31.CrossRefPubMedGoogle Scholar
  57. 57.
    Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial. Lancet. 2007;370:1209–18.CrossRefPubMedGoogle Scholar
  58. 58.
    Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24:431–6.CrossRefPubMedGoogle Scholar
  59. 59.
    Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99:4525–30.CrossRefPubMedGoogle Scholar
  60. 60.
    Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118(7):2427–37.PubMedGoogle Scholar
  61. 61.
    Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD, et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood. 2006;108:618–21.CrossRefPubMedGoogle Scholar
  62. 62.
    Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98(1):210–6.CrossRefPubMedGoogle Scholar
  63. 63.
    Dredge K, Horsfall R, Robinson SP, Zhang LH, Lu L, Tang Y, et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res. 2005;69:56–63.CrossRefPubMedGoogle Scholar
  64. 64.
    Hideshima T, Raje N, Richardson PG, Anderson KC. A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma. Ther Clin Risk Manag. 2008;4(1):129–36.PubMedGoogle Scholar
  65. 65.
    Richardson P, Jagannath S, Schlossman R, Weller E, Zeldenrust S, Rajkumar SV, et al. A multi-center, randomized, phase II study to evaluate the efficacy and safety of two CC-5013 dose regimens when used alone or in combination with dexameyhasone (Dex) for the treatment of relapsed or refractory multiple myeloma (MM). Blood. 2002;100:104a.Google Scholar
  66. 66.
    Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006;108:3458–64.CrossRefPubMedGoogle Scholar
  67. 67.
    Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123–32.CrossRefPubMedGoogle Scholar
  68. 68.
    Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133–42.CrossRefPubMedGoogle Scholar
  69. 69.
    Reece D, Song KW, Fu T, Roland B, Chang H, Horsman DE, et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood. 2009;114(3):522–5.CrossRefPubMedGoogle Scholar
  70. 70.
    Rajkumar S, Jacobus N, Callander R, Fonseca R, Vesole MV, Williams R, et al. Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: analysis of response, survival, and outcome. Abstract 8504. In: American Society of Clinical Oncology Annual Meeting; 2008.Google Scholar
  71. 71.
    Palumbo A, Falco P, Benevolo G, Canepa L, D’Ardia S, Gozzetti A, et al. Oral lenalidomide plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma. J Clin Oncol. 2006;24(18s):7518.Google Scholar
  72. 72.
    Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2003;101:1530–4.CrossRefPubMedGoogle Scholar
  73. 73.
    Orlowski RZ, Hall M, Voorhees P, Hogan C, Humes E, Johri A, et al. Phase I study of the proteasome inhibitor bortezomib (PS-341, Velcade) in combination with pegylated liposomal doxorubicin (Doxil) in patients with refractory helatologic malignancies. Blood. 2002;100:105a.Google Scholar
  74. 74.
    Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609–17.CrossRefPubMedGoogle Scholar
  75. 75.
    Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127:165–72.CrossRefPubMedGoogle Scholar
  76. 76.
    Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–98.CrossRefPubMedGoogle Scholar
  77. 77.
    San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906–17.CrossRefPubMedGoogle Scholar
  78. 78.
    Jagannath S, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2007;21:151–7.CrossRefPubMedGoogle Scholar
  79. 79.
    Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood. 2005;106(9):2977–81.CrossRefPubMedGoogle Scholar
  80. 80.
    Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–20.CrossRefPubMedGoogle Scholar
  81. 81.
    Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996;334(8):488–93.CrossRefPubMedGoogle Scholar
  82. 82.
    Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002;20:3719–36.CrossRefPubMedGoogle Scholar
  83. 83.
    Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Ceccolini M, et al. Superior complete response rate and progression-free survival after autologous transplantation with up-front velcade-thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma. Blood (ASH Annual Meeting Abstracts). 2008;112:158.Google Scholar
  84. 84.
    Richardson P, Jagannath S, Jakubowiak A, Lonial S, Raje N, Alsina M, et al. Lenalidomide, bortezomib, and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (MM): encouraging response rates and tolerability with correlation of outcome and adverse cytogenetics in a phase II study. Blood (ASH Annual Meeting Abstracts). 2008;112:1742.Google Scholar
  85. 85.
    Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K. New drugs for myeloma. Oncologist. 2007;12(6):664–89.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Jacob P. Laubach
    • 1
    Email author
  • Paul G. Richardson
    • 1
  • Kenneth C. Anderson
    • 1
  1. 1.Department of Medical Oncology, Division of Hematologic MalignanciesDana Farber Cancer InstituteBostonUSA

Personalised recommendations